What are the functions and effects of Ripotinib?

Repotrectinib (Repotrectinib) is a new, highly selective small molecule tyrosine kinase inhibitor that specifically targets ROS1 and NTRK gene fusion-related pathways and has demonstrated significant preclinical and preliminary clinical efficacy in the treatment of tumors driven by certain gene mutations. Its main indications cover patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and NTRK gene fusion-positive solid tumors, especially those who are ineffective or resistant to standard therapies or have no other suitable alternatives. Reputinibhas attracted the attention of the international oncology community because it can inhibit a series of complex and clinically highly drug-resistant mutant fusion proteins, including CD74-ROS1G2032R, CD74-ROS1D2033N, etc. These proteins are commonly found in patients who have developed drug resistance after previously receiving other TKI treatments.

InROS1-positive non-small cell lung cancer (NSCLC), The mechanism of action of Ripotinib is to precisely bind to the activation site of ROS1 fusion protein and block its abnormal signal transduction, thereby inhibiting the unlimited proliferation of tumor cells. ROS1 gene fusion is a type of driver mutation that usually promotes cell growth by activating PI3K-AKT, JAK-STAT, MAPK and other signaling pathways. Studies have shown that this drug can effectively overcome the problem of resistance to first- or second-generation ROS1 inhibitors such as crizotinib and entrectinib due to G2032R and other mutation sites, so it has a particularly prominent role in patients with "post-TKI resistance". In addition, the molecular structure design of repotinib is highly compact and penetrating, allowing it to more effectively cross the blood-brain barrier and has potential in controlling intracranial metastasis, which has clinical significance for NSCLC patients with a high risk of brain metastasis.

In the treatment ofNTRK fusion-positive solid tumors, Ripotinib also shows strong target selectivity. Although NTRK1/2/3 gene fusion is relatively rare in various solid tumors, when it occurs, it is usually the core driver of cancer. Traditional therapies have limited effect on such rare mutations, and the precise targeting mechanism of ripertinib provides a new treatment path for these patients, especially for patients who have failed treatment with larotrectinib or entrectinib.

In terms of pharmacokinetics, repotinib is administered orally daily and the recommended starting dose is160 mg once daily, then adjust to 160 mg twice daily. In terms of safety, the drug will not prolong the QTc interval by more than 20 milliseconds on average at the current dose, which means it has less impact on cardiac rhythm and is safer than other TKI drugs. However, patients still need to undergo regular electrocardiogram monitoring during treatment to prevent rare cardiotoxic reactions. Common adverse reactions include dizziness, nausea, fatigue, dysgeusia, etc., most of which are mild to moderate and well controllable. Due to its clear therapeutic window, doctors can flexibly adjust the dosage according to the patient's tolerance during actual medication, taking into account both efficacy and safety.

Although repotinib is still in the introduction or approval stage in China, it has obtained accelerated approval status from the U.S. FDA and has been included in important recommendations for the treatment of ROS1-positive NSCLC and NTRK fusion-positive solid tumors. With the development of global precision medicine, this drug is expected to become one of the important first choices for targeted treatment of drug-resistant driver mutations in the future. Ripotinib represents a breakthrough treatment option for patients who have progressed on first- or second-generation ROS1/NTRK inhibitors.

Reference materials:https://www.drugs.com/mtm/repotrectinib.html